Regeneron Pharmaceuticals
REGN
$766.02
+2.60%
Regeneron Pharmaceuticals is a leading biotechnology company that discovers, develops, and commercializes therapeutics for serious medical conditions, primarily focusing on eye diseases, immunology, cardiovascular disease, and cancer. The company is distinguished as a market leader in ophthalmology with Eylea and a major player in immunology through its blockbuster drug Dupixent, developed in collaboration with Sanofi. The current investor narrative is dominated by the robust growth trajectory of Dupixent offsetting competitive pressures on Eylea, coupled with strategic pipeline diversification through partnerships in gene editing and oncology, as evidenced by recent deals like the one with Telix Pharma targeting solid tumors.…
REGN
Regeneron Pharmaceuticals
$766.02
Related headlines
REGN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $995.83 and implied upside of +30.0% versus the current price.
Average Target
$995.83
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$613 - $996
Analyst target range
Regeneron is covered by 11 analysts, and the institutional ratings show a consensus that leans bullish, with recent actions including reiterations of 'Buy', 'Overweight', and 'Outperform' from firms like Guggenheim, JP Morgan, and Oppenheimer, alongside 'Equal Weight' or 'Sector Perform' ratings from others like Morgan Stanley and RBC Capital. The average analyst revenue estimate for the coming period is $21.44 billion, with a range from $19.64 billion to $23.46 billion, and the average EPS estimate is $72.19, ranging from $64.32 to $81.02, indicating a wide spread that reflects uncertainty around the precise growth trajectory and competitive dynamics. The wide target range for both revenue and EPS signals high uncertainty among analysts, typically related to the evolving commercial performance of Dupixent, the impact of competition on Eylea, and the success of the pipeline, which can lead to higher stock volatility as new data emerges.
REGN Technical Analysis
Regeneron's stock is in a sustained uptrend over the past year, evidenced by a 33.28% one-year price increase, though it is currently consolidating below its recent highs. The stock closed at $750.57, which positions it at approximately 85% of its 52-week range ($476.49 to $821.11), indicating it is trading closer to the upper bound of its yearly band, a zone that can signal either strong momentum or potential overextension. Recent momentum shows a deceleration, with the stock up only 0.87% over the past month and 2.39% over the past three months, a significant slowdown compared to the 29.85% gain over the last six months; this divergence from the longer-term trend suggests a period of consolidation or profit-taking after a sharp rally. The stock's beta of 0.397 indicates it has been significantly less volatile than the broader market, which is unusual for a biotech but may reflect its mature product portfolio and stable cash flows. Key technical support is anchored at the 52-week low of $476.49, while immediate resistance is at the 52-week high of $821.11; a decisive breakout above resistance would signal a resumption of the primary bull trend, whereas a breakdown below the recent consolidation range near $730 could indicate a deeper correction.
Beta
0.40
0.40x market volatility
Max Drawdown
-28.1%
Largest decline past year
52-Week Range
$476-$821
Price range past year
Annual Return
+30.3%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | +3.3% | +8.5% |
| 3m | +1.7% | +2.8% |
| 6m | +32.5% | +4.6% |
| 1y | +30.3% | +32.3% |
| ytd | -1.3% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Regeneron's revenue trajectory remains positive but shows signs of deceleration; Q4 2025 revenue was $3.884 billion, representing a modest 2.51% year-over-year growth, a slowdown from the stronger growth rates seen in prior quarters of 2025. The company's profitability is robust, with Q4 2025 net income of $844.6 million and a gross margin of 84.95%, though net margins have compressed from the 38.9% seen in Q3 2025 to 21.7% in Q4, reflecting typical quarterly variability and investment. The balance sheet and cash flow position are exceptionally strong, highlighted by a debt-to-equity ratio of just 0.087, a current ratio of 4.13 indicating ample liquidity, and trailing twelve-month free cash flow of $4.08 billion, which provides significant internal funding capacity for R&D and shareholder returns.
Quarterly Revenue
$3.9B
2025-12
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$4.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Given Regeneron's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 17.92x and a forward PE of 14.32x, with the forward multiple's discount to the trailing figure implying the market expects earnings growth. Compared to typical biotechnology industry averages (which often range higher due to growth expectations), Regeneron's current multiples appear reasonable, if not conservative, for a company with its profitability and scale, though a direct industry average from the provided data is not available for a quantified premium/discount analysis. Historically, the stock's own trailing PE has fluctuated significantly, from highs above 36x in early 2024 to lows near 10x in late 2025; the current PE of 17.92x sits near the midpoint of this recent historical range, suggesting the market is pricing in a balanced outlook that acknowledges growth drivers like Dupixent alongside competitive risks.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple